A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 68
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LA
Long Form : locally advanced
No. Year Title Co-occurring Abbreviation
2020 Tumor-node-metastasis staging and treatment patterns of 73,167 patients with lung cancer in Brazil. AM
2019 Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01). CRT, CS, CT, HOPS, MDCT, OS, UR-PC
2019 Extrafascial robot-assisted laparoscopic radical prostatectomy in locally advanced prostate cancer. PCa, RP
2019 Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. BR, CRT, OS, PDAC, PET, RFS, TNT
2019 First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. BR-A, CI, ECOG PS, HR, OS, PDAC, PR
2019 Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. BRPC, GEM
2019 How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. BR, CRT, FLX, OS, PAC
2019 Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. MPC, ORR, OS, TTP
2019 Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. ccrt, OS, PFS
10  2019 Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. BR, CT, DFS, OS, PDAC
11  2019 Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC). CTC, HNSCC, ICD, TLRs
12  2019 Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC. aHR, CI, CSM, ES, OPSCC, OS
13  2018 A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. BR, GSL, NAC, PC
14  2018 A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. AR, CAB, CI, RM, SGC
15  2018 A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. MBC
16  2018 Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. BR, CHA, OS, PDA
17  2018 De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease. EGFR, HPV, mAbs, OPC, QOL
18  2018 Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. BR, PC, SBRT
19  2018 Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. BR, ICT, LPFS, PDAC, SABR's
20  2018 Safety and efficacy of weekly versus three-weekly paclitaxel plus platinum neoadjuvant chemotherapy in patients with locally advanced squamous cell head and neck carcinoma: A pilot study. SCCHN
21  2018 Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. BR, PDAC
22  2018 Surgery for Pancreatic Cancer after neoadjuvant treatment. BR, PDAC
23  2017 A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). NSCLC, SBRT
24  2017 CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. BR, CT, DFS, NCCN
25  2017 Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer. OS
26  2017 Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis. BLR, ITT, OS, PaC
27  2017 Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. BR, NAT
28  2017 Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. EOX, OS, PFS
29  2017 Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. BL, CT, MS
30  2017 Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. EGFR, HR, OR, OS, PDACs, RCTs
31  2017 Tumour auto-contouring on 2d cine MRI for locally advanced lung cancer: A comparative study. MRI, PCNN
32  2016 CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. BR, HR, OS, PDAC
33  2016 Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: An investigation of distant metastasis. CR, DMs, OS, OSCC, PFS, R/M
34  2016 Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review. NACT, RR
35  2016 Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder? DSR, EFS, FFPE, GIST, IM, LR, NA, RR
36  2016 Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. EGFR, SCCHN
37  2016 Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma. BCC, EAS
38  2015 Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. CI, EGFR, ERCC, HR, OS, PFS
39  2015 Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. CGE, ENI, IF, IMPT, NSCLC, PTV
40  2015 Long-Term Survival After High-Dose-Rate Brachytherapy for Locally Advanced or Recurrent Colorectal Adenocarcinoma. CRC, HDR, IORT, LR
41  2015 Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. BR, DFS, PAC, pMR
42  2015 Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT. CCRT, CT, NSCLC, OUH, PET-CT, PET-CT9, PFS, PS
43  2015 Prophylactic Cranial Irradiation for Patients With Locally Advanced Non-Small-Cell Lung Cancer at High Risk for Brain Metastases. NSCLC, PCI
44  2015 Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. BL
45  2014 Age does not worsen the efficacy nor tolerance to combined induction therapies in locally advanced non-small cell lung cancer. NSCLC
46  2014 Down-staging following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: Does timing of surgery really matter? NACTRT, pCR, SSS, TRG, TRS
47  2013 Age distribution of patients with advanced non-melanoma skin cancer in the United States. MET, NMSC
48  2013 Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer. DLT, L1D, L2D, NSCLC, PD, PR, RD, SD, TRT
49  2013 Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study. RT, SCCHN
50  2013 Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? PDAC
51  2013 Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy. IM, LN, OS, pCR, PFS, TRG
52  2011 Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. MBC, OS, PD, TTP
53  2010 Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck. ICT, RT, SCCHN
54  2009 Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck. CRT, DIP, NCI-CTC2, SCCHN, WHO
55  2009 Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. C/G, KP, PFS
56  2009 Surgery for patients with gastric cancer in the terminal stage of the illness - TNM stage IV. MMC, SM
57  2008 Docetaxel in the treatment of squamous cell carcinoma of the head and neck. CCRT, ICT, M/R, RT, SCCHN
58  2008 Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. EGFR, MoAb, RT, SCCHN
59  2007 Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. RT
60  2007 Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. ER-beta, HR, ORR, PgR
61  2007 Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. CRT, CT, GERCOR, OS, PFS
62  2007 Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. DCF
63  2005 Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. DPD, TNF-alpha, TP
64  2004 Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. CR, DC, NSCLC, PR, TRT
65  2003 Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. DFS, IL-2, RCC
66  2003 Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. CI, FU
67  2001 Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). 5-FU, CI, FOLFUGEM
68  1993 Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. DI, RM, TTP